Enzymotec Ltd. Revenue Growth Rates (ENZY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Enzymotec Ltd.  (ENZY)
 

ENZY's Revenue Growth by Quarter and Year

Enzymotec Ltd.'s Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENZY Revenue (in millions $) FY 2016 FY 2015 FY 2014 FY 2013
4th Quarter December 47.70
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 47.70





ENZY Revenue fourth quarter 2016 Y/Y Growth Comment
Enzymotec Ltd. reported decrease in Revenue in the fourth quarter 2016 by -5.35% to $ 47.70 millions, from the same quarter in 2015.
This represents worst decline in recent Company history.

Looking into fourth quarter 2016 results within Biotechnology & Pharmaceuticals industry 35 other companies have achieved higher Revenue growth. While Enzymotec Ltd.' s Revenue decline of -5.35% ranks overall at the positon no. 3031 in the fourth quarter 2016.


ENZY Revenue ( Y/Y Growth %) 2016
 2015 2014 2013
4th Quarter December -5.35 % 6.99 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   -5.35 % 6.99 % - -

Financial Statements
Enzymotec Ltd.'s fourth quarter 2016 Revenue $ 47.70 millions ENZY's Income Statement
Enzymotec Ltd.'s fourth quarter 2015 Revenue $ 50.39 millions Quarterly ENZY's Income Statement


ENZY Revenue (Quarter on Quarter Growth %)

 2016
 2015 2014 2013
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   -5.35 % 6.99 % - -


Back to ENZY Growth rate Comparisons >> Back to ENZY Growth rate Comparisons >>


Revenue fourth quarter 2016 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #36
Healthcare Sector #380
Overall #3031

Revenue Y/Y Growth Statistics
High Average Low
6.98 % 0.82 % -5.35 %
(Dec 31 2015)   (Dec 31 2016)
Revenue fourth quarter 2016 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #36
Healthcare Sector #380
Overall #3031
Revenue Y/Y Growth Statistics
High Average Low
6.98 % 0.82 % -5.35 %
(Dec 31 2015)   (Dec 31 2016)

Revenue by Quarter for the Fiscal Years 2013, 2014, 2015, 2016

Enzymotec Ltd.'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENZY's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENZY's IV. Quarter Q/Q Revenue Comment


Enzymotec Ltd.'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2016)		 12 Months Ending
(Dec 31 2015)		 12 Months Ending
(Dec 31 2014)		 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 47.70 $ 50.39 $ 47.10 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) -5.35 % 6.98 % -27.51 % - -
Year on Year Revenue Growth Overall Ranking # 2618 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -5.35 % 6.98 % -27.51 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 1307 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2016 Enzymotec Ltd. reported a decrease in Revenue by -5.35% year on year, to $48 millions, compare to the 6.98% growth at Dec 31 2015.

In the Healthcare sector 348 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2618.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 19
Healthcare Sector # 349
Overall # 2618

Revenue TTM Y/Y Growth Statistics
High Average Low
-5.35 %
 -5.35 %
-5.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 215
S&P 500 # 1307
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2016 Enzymotec Ltd. reported a decrease in Revenue by -5.35% year on year, to $48 millions, compare to the 6.98% growth at Dec 31 2015.

In the Healthcare sector 348 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2618.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 19
Healthcare Sector # 349
Overall # 2618

Revenue TTM Y/Y Growth Statistics
High Average Low
-5.35 %
-5.35 %
-5.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 215
S&P 500 # 1307




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENZY's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Dec 31 2016 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2016
Syndax Pharmaceuticals Inc 0.00%$ 0.000 millions
Acer Therapeutics Inc 0.00%$ 0.000 millions
Phibro Animal Health Corporation-0.09%$ -0.091 millions
Misonix Inc -0.15%$ -0.149 millions
Reata Pharmaceuticals Inc -0.19%$ -0.192 millions
Abaxis Inc-0.20%$ -0.197 millions
Magellan Health inc -0.42%$ -0.422 millions
Quidelortho Corp-0.63%$ -0.629 millions
Tandem Diabetes Care Inc -0.71%$ -0.714 millions
Meridian Bioscience Inc -0.74%$ -0.744 millions
Merck and Co Inc -0.98%$ -0.979 millions
Hanger inc.-1.61%$ -1.610 millions
Bruker Corporation-1.65%$ -1.652 millions
Alpha Pro Tech Ltd -1.87%$ -1.874 millions
Alerislife Inc -2.02%$ -2.018 millions
Perrigo Company Plc-2.05%$ -2.053 millions
Becton Dickinson And Company-2.14%$ -2.143 millions
Brookdale Senior Living Inc -2.17%$ -2.172 millions
Sangamo Therapeutics Inc -2.18%$ -2.182 millions
Haemonetics Corporation-2.38%$ -2.375 millions
Encision Inc -2.74%$ -2.739 millions
Pfizer Inc-2.99%$ -2.990 millions
Hill rom Holdings Inc -3.60%$ -3.600 millions
Tenet Healthcare Corp-3.68%$ -3.676 millions
Chembio Diagnostics Inc -3.75%$ -3.754 millions
Fate Therapeutics Inc -4.55%$ -4.554 millions
Adicet Bio Inc -4.65%$ -4.649 millions
Reshape Lifesciences Inc-4.70%$ -4.698 millions
Nektar Therapeutics-4.88%$ -4.877 millions
Emergent Biosolutions Inc -5.08%$ -5.082 millions


About Enzymotec Ltd. Revenue Growth Rates (ENZY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.